We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Prognosis and Survival in Acute Myelogenous Leukemia

Muath Dawod and Amr Hanbali

*Department of Hematology and Oncology / Henry Ford Hospital
Detroit, Michigan
USA*

1. Introduction

Progress in understanding the prognosis and survival in acute myelogenous leukemia (AML) has been dramatic over the last few decades. Traditionally, clinical risk factors such as age and performance status have been the main prognostic factors in AML. However, recent advances in cytogenetic studies and molecular markers in AML have revolutionized our approach to this disease. These have changed our understanding of AML as a heterogeneous group of diseases rather than a single disease, provided greater insight not only in understanding disease biology but also into predicting response to therapy and helped in the development of risk stratification-based treatment approach.

In 2010, there are about 12,330 new cases in the United States which represent about 0.8% and 29% of all new cancer and leukemia cases respectively. With about 8,950 estimated deaths related to AML, this represents about 1.6% of cancer related deaths in 2010. (American Cancer Society, 2010)

Although there has been some improvement in survival for AML patients over the last few decades, mainly in younger age groups as shown in figure 1, AML long term survival is still a big challenge. In the United States, data from Surveillance Epidemiology and End Results (SEER) dataset for 2001 to 2007 showed 5-year overall survival (OS) of 22.6% for all AML patients. There is still a lot to be done especially in the oldest age group (>65 years), that is showing a dismal 5-year OS of less than 5%, See Figure 2. This is of particular concern as more than half of the patients diagnosed in 2000-2004 were over 65 years old. (Howlader et al., 2011).

2. Clinical prognostic factors

2.1 Age

AML is seen more commonly in the elderly with median age at diagnosis of 66 with incidence increases dramatically after age of 55, See figure 3. Data from SEER (see figure 2) as well as from major studies of the largest cooperative groups including the Medical Research Council (MRC), the Southwest Oncology Group/Eastern Cooperative Oncology Group (SWOG/ECOG), AML cooperative group (AMLCG) and the Cancer and Leukemia Group B (CALGB) that included elderly patients have shown consistently worse outcome in this patient population, See figure 4. (Slovak et al., 2000; Byrd et al., 2002; Schoch et al., 2004a; Grimwade & Hill., 2009)

Fig. 1. Period estimates of 5-year relative survival of patients with AML by major age groups in defined calendar periods from 1980-1984 to 2000-2004. (Pulte et al., 2008).

Fig. 2. Age and sex-associated with 5-year relative survival in patients with AML in the United States, 1996-2003 (From SEER cancer statistics, National Cancer Institute, 2007.)

Fig. 3. Age-Specific incidence rates for AML from 2003 to 2007. (Altekruse et al., 2010).

Fig. 4. Survival curves according to age groups. a: Patients treated in MRC AML trials (AML10, 11, 12, 14 and 15) (Smith et al. , 2011). b: Patients treated in AMLCG trials (AMLCG 1992, AMLCG 1999 and AMLCG APL trials) (Schoch et al., 2004a)

The worse outcome in elderly population is related to two components: resistance to treatment and treatment-related death. It is believed that most of treatment failure in elderly is related to the first component. This is mainly related to distinct biological and clinical features such as higher percentage of poor cytogenetics, higher incidence of multidrug resistance protein (MDR) and preceding hematological disease, all of which are associated independently with worse prognosis in AML. (Lieth et al., 1997; Estey 2007). For example, in retrospective analysis from five SWOG clinical trials more than 50% of patients >75 years old had poor cytogenetics which translated into complete remission (CR) rate of 33%, See figure 5, table 1. (Appelbaum et al., 2006a)

Fig. 5. Percentage of patients in the different cytogenetic risk groups by age category in five SWOG clinical trials (Appelbaum et al., 2006a).

	Younger than 56 y	56-65 y	66-75 y	Older than 75 y
No. patients	368	246	274	80
Response, no. (%)				
CR	235 (64)	113 (46)	108 (39)	26 (33)
Resistant disease	99 (27)	91 (37)	101 (37)	29 (36)
Median overall survival, no. (95% CI)	18.8 (14.9-22.6)	9.0 (8.1-10.2)	6.9 (5.4-7.7)	3.5 (1.4-6.1)
No. patients with CR	235	113	108	26
Median disease-free survival, no. (95% CI)	21.6 (15.8-25.5)	7.4 (6.5-8.8)	8.3 (6.3-10.2)	8.9 (5.8-10.8)

Table 1. CR rates in different age groups in the same patient population (Appelbaum et al., 2006a).

The second component of treatment failure is treatment-related death. This is mainly related to the worse performance status and organ function in this age group. Multiple studies have shown age along with poor performance status as very strong predictors of early post-induction mortality in AML, See table 2, Figure 6. (Appelbaum et al., 2006a; Juliusson et al., 2009).

This has motivated researchers to develop different prognostic and predictive models including clinical and laboratory variables that can help physicians deciding treatment in this challenging patient population. (Krug et al., 2010; Kantarjian et al., 2010)

Even after accounting for the above factors, elderly patients tend to have worse outcome with less CR rate and higher mortality rate. In two different reports from SWOG and AMLCG, elderly patients with favorable cytogenetic have worse outcome compared to younger patients. (Schoch et al., 2004a; Appelbaum et al., 2006a)

The dismal prognosis in elderly population has another component which is undertreatment. While AML is more common in elderly, a large number of these patients do not receive intensive chemotherapy. This is because they are more likely to have poor

performance status and comorbidities at diagnosis and therefore less frequently judged to be fit for induction therapy. Menzin et al., reviewed SEER data of AML in elderly patients. Among 2657 patients age > 65 years reviewed, only 30% of patients underwent intensive chemotherapy. Juliusson et al reported similar numbers from the Swedish Acute Leukemia Registry with only 45% of patients in age group 70-74 offered treatment as compared to 92% in 60-64 age group and 98% in <50 age group (Juliusson et al., 2009).

	Younger than 56 y	56-65 y	66-75 y	Older than 75 y
No. patients	364	242	270	79
Early deaths* by performance status, no./no. total patients (%)				
0	3/129 (2)	8/72 (11)	9/73 (12)	2/14 (14)
1	6/180 (3)	6/112 (5)	20/126 (16)	7/40 (18)
2	1/46 (2)	6/34 (18)	16/52 (31)	7/14 (50)
3	0/9 (0)	7/24 (29)	9/19 (47)	9/11 (82)

Table 2. Mortality within 30 days of induction treatment according to age group and performance status in 5 clinical SWOG trials (Appelbaum et al., 2006a).

Fig. 6. Mortality within 30 days of induction treatment according to age group and performance status the Swedish acute leukemia registry (Juliusson et al., 2009).

So when interpreting data from various clinical trials we have to keep in our minds that the patient population in clinical trials includes only a subset of elderly patients with AML and survival numbers achieved could be an overestimate in this patient population. In the same report from Menzin et al including treated and untreated AML patients, patients older than 65 years had a median survival of two months with two-year OS of 6% (Menzin et al., 2002).

2.2 Performance status

Different clinical trials have consistently showed worse outcome in patients with poor performance. It is considered the strongest predictor of 30-day mortality after induction therapy, See table 2, Figure 6. (Appelbaum et al., 2006a; Juliusson et al., 2009). Poor performance usually reflects comorbidities and organ dysfunction. Assessing this parameter in elderly patients can be difficult. Acute infection or decompensation can easily change performance status and confuse our assessment of baseline performance status. Clinical trials exclude patients with poor performance status, so when reviewing data from any clinical trial we have to keep in our minds that it excludes a major part of patients who are rendered ineligible. This selection bias is more pronounced in elderly population as fit elderly are more likely to receive treatment.

2.3 Prior hematological disease

The prior diagnosis of myelodysplastic (MDS) or myeloproliferative (MPD) disease is well established as a poor prognostic factor in AML patients. While the poor survival is more associated with high prevalence of advanced age and poor cytogenetics in this patient population, it is still an independent prognostic factor after adjusting for both variables. Longer interval from onset of MDS or MPD disease to AML negatively affected outcomes in this patient population. One explanation is that a protracted history of prior hematological disease may select for higher rates of chemotherapy resistance after AML develops. Prior treatment for MDS is another poor prognostic factor in this patient population. (Bello et al., 2011).

2.4 Therapy-related AML

People exposed to cytotoxic agents are at higher risk of developing AML among other myeloid neoplasms. Therapy-related AML (t-AML) represents about 10-15% of all cases of AML (Schoch et al., 2004b). It is considered a poor prognostic factor. Goldstone et al. reported OS of 30% compared to 44% in de novo AML (Goldstone et al., 2002). In another report from Kayser et al, Outcome of patients with t-AML was significantly inferior with 4-year OS of 25.5% compared to 37.9% in de novo AML. (Kayser et al., 2011)

The risk is highest after exposure to two classes of cytotoxic agents: topoisomerase II inhibitors and alkylating agents. The current WHO classification does not subcategorize t-AML based on agents involved. This is mainly due the fact that most patients developing t-AML have been exposed to both types and it is not feasible to discriminate according to the previous therapy. (Swerdlow et al., 2008)

Each class related-AML has certain characteristics. While alkylating agents related-AML frequently is preceded by myelodysplastic phase and a long interval between exposure and development of AML (36-72 months), topoisomerase II related-AML usually presents without myelodysplastic phase and has an interval of usually 6 to 36 months. While alkylating agents are usually associated with unbalanced cytogenetic abnormalities involving chromosome 5 and 7 as well as complex karyotype, patients with topoisomerase II inhibitors related t-AML are more likely to have balanced translocations involving MLL at 11q23, NUP98 at 11p15, RUNX1 at 21q22 and RARA at 17q21.

t-AML is commonly associated with abnormal karyotype ranging between 69 to 96%. Cytogenetic abnormalities in t-AML are the same described in de novo AML but with different frequencies. In one report, 46% of t-AML patients had unfavorable cytogenetic

profile as compared to 20% in de novo AML and only 10% had normal cytogenetics versus 40% in de novo AML. Similar distribution has been observed in other trials as well. (Schoch et al., 2004b ; Grimwade & Hill 2009; Kayser et al., 2011)

Patients with t-AML tend to be older than de novo AML patients. In one report , median age of t-AML was 57.8 years versus 53.2 years in de novo AML. (Kayser et al., 2011)

While the above factors contribute to the worse outcome seen in t-AML, inferior survival and response rate has been observed in all age and cytogenetic subgroups (Grimwade & Hill 2009; Borthakur et al., 2009), See figure 7.

Fig. 7. Survival curves according to cytogenetics subgroups for patients treated in MRC AML trials (AML10, 11, 12, 14 and 15) with t-AML and de novo AML (Grimwade & Hill 2009).

2.5 Others

Clinical markers of high tumor burden like high LDH , high peripheral white blood cell (WBC) count and need for cytorreduction therapy are reported to be of adverse impact on prognosis. As will be discussed later in details, certain molecular abnormalities (FLT3 or KIT mutations) are more associated with high WBC count which could be the actual factor contributing to the prognosis. So much of the prognostic impact of leukocytosis may reflect the molecular abnormalities driving the proliferation. (Dalley et al., 2001; Martin et al., 2000; Burnett et al., 1999) Extramedullary involvement has been associated with worse outcome as well. (Change et al., 2004)

3. Karyotype

50 to 60 % of adult patients with de novo AML have karyotype abnormalities. Cytogenetics is the most powerful prognostic factor in AML. This has been illustrated in several analyses from small single institution studies as well as large multi-institutional trials from various research groups. Its importance has exceeded other variables by consistently showing strong prognostic value in predicting CR, risk of relapse as well as survival, See figure 7

(Grimwade & Hill 2009; Byrd et al., 2002; Slovak et al., 2000). Therefore it is the single most important factor that provides a framework for the current risk-stratified treatment approach in AML. This is clearly reflected on the current WHO classification of AML in which different groups are specified according to the cytogenetic abnormalities. (Swerdlow et al., 2008)

While there is agreement among different groups on defining the favorable cytogenetics group, there is variation on assigning the rest of karyotype abnormalities in the other two groups (i.e. intermediate and adverse). This could be related to variation in patient characteristics, treatment protocols among various trials, as well as the relatively small number of patients having a certain cytogenetic abnormalities in each trial. Table 3 is showing different cytogenetics risk groups in major cooperative groups clinical trials.

	Original MRC	SWOG/ECOG	CALGB	GIMEMA/AML10	German AMLCG	HOVON/SAKK	Refined MRC
Favorable	t(15;17) t(8;21) inv(16)/t(16;16)	t(15;17) t(8;21) [lacking del(9q), complex, ie, ≥ 3 unrel abn] inv(16)/t(16;16)/del(16q)	t(15;17) t(8;21) inv(16)/t(16;16)	t(15;17) t(8;21) inv(16)/t(16;16)	t(15;17) t(8;21) inv(16)/t(16;16)	t(15;17) t(8;21) alone inv/del(16) and lacking unfav abn	t(15;17) t(8;21) inv(16)/t(16;16)
Intermediate	Normal Other non-complex	Normal +6, +8, -Y, del(12p)	Normal Other non-complex	Normal -Y	Normal Other non-complex	Normal Other non-complex	Normal Other non-complex
Adverse	abn(3q) -5/del(5q) -7 complex [≥ 5 unrel abn] Excluding those with favorable changes	abn(3q),(9q),(11q),(21q) abn(17p) -5/del(5q) -7/del(7q) t(6;9) t(9;22) complex [≥3 unrel abn]	inv(3)/t(3;3) -7 t(6;9) t(6;11) t(11;19) +8 complex (≥ 3 unrel abn) Excluding those with favorable changes	Other	inv(3)/t(3;3) -5/del(5q) -7/del(7q) abn(11q23) del(12p) abn(17p) complex (≥ 3 unrel abn)	abn(3q) -5/del(5q) -7/del(7q) abn(11q23) t(6;9) t(9;22) complex (≥ 3 unrel abn)	abn(3q) [excluding t(3;5)] inv(3)/t(3;3) add(5q)/del(5q)/-5,-7/add(7q) t(6;11) t(10;11) t(9;22) -17 abn(17p) with other changes Complex (> 3 unrel abn) Excluding those with favorable changes

Unrel abn indicates unrelated abnormality; abn, abnormal.

Table 3. Classification of different cytogenetics risk groups in major cooperative groups clinical trials. (Grimwade & Hill , 2009).

3.1 Favorable risk

Acute promyelocytic leukemia (APL) with t(15;17) translocation as well as AML with core binding factor (CBF) abnormalities [t(8;21) and inv(16)/t(16;16)] fall in the favorable risk group. They represent around 15% of all AML cases in adults. The favorable outcome in this group has been consistently reported by different research group trials. See Figures 7 and 8.

3.1.1 t(15;17)

APL represents a distinct subtype of AML with characterstic morphological features, clinical presentation, and treatment regimen that incorporates all trans retinoic acid (ATRA). Different clinical trials have reported excellent outcomes with CR rates of more than 90 %. If an ATRA-based regimen of induction, consolidation, and maintenance is used, rates of 3-year OS exceed 85 %. In one report from European APL group 10-year OS rate was 77%. (Ades et al. 2010; Lo-Coco et al. 2010; Sanz et al. 2010) While it carries a good prognosis in general, it is important to

notice that patients with age less than 30 years and WBC count less than 10,000/microL at presentation have superior event-free survival. (Asou et al., 1998)

About 40% of patient with APL have associated chromosomal abnormalities. These additional abnormalities have no impact on treatment outcome. (De Botton et al., 2000; Slack et al., 1997)

3.1.2 t(8;21)

It has been consistently reported to be of favorable prognosis with CR rates exceeding 87-90% and a 5-year survival of at least 40-65% (Grimwade et al., 2010; Appelbaum et al., 2006a). Along with AML with Inv(16)/ t(16;16), AML with t(8;21) comprise CBF leukemias. In addition to sharing similar pathogenesis, the CBF leukaemias share the characteristics of sensitivity to high-dose cytarabine (HDAC) (Grimwade et al., 1998; Slovak et al., 2000; Byrd et al., 2002). Furthermore, the outcome can be improved substantially by post-remission therapy with HDAC. (Byrd et al., 1999; Palmieri et al., 2002)

While there is agreement on prognosis in AML with isolated t(8;21), there has been inconsistency when defining the prognostic significance of additional cytogenetic abnormalities. Three different small trials have showed poor prognosis with the presence of deletions of the long arm of chromosome 9 (del(9q)) (Schoch et al., 1996) and karyotype complexity (Appelbaum et al., 2006b). On the other side, one large cohort showed no negative impact on prognosis; on the contrary, loss of the Y chromosome in male subjects was associated with a trend for better overall survival (Grimwade et al., 2010).

On the other hand, adverse prognostic significance has been linked to high WBC or absolute granulocyte count, the presence of granulocytic sarcomas, expression of the neural cell adhesion molecule CD56 on leukemic blasts and high WBC index. (Nguyen et al., 2002)

3.1.3 Inv(16)/ t(16;16)

While it is commonly grouped with AML associated with t(8;21) due to similar pathogenesis and outcome, there are few differences. AML associated with inv(16) has different morphological features usually of FAB M4Eo morphology and is less likely to have secondary cytogenetic changes (Byrd et al., 1999, 2004; Nguyen et al., 2002; Delaunay et al., 2003). The presence of such abnormalities, particularly +22, predicted a better outcome in AML associated with inv(16), t(16;16). (Schlenk et al., 2004; Marcucci et al., 2005)

As with t(8;21), the outcome of adults with AML with Inv(16)/ t(16;16) can be improved substantially by intensive post-remission therapy with HDAC. Byrd et al reported the 5-year relapse rate was significantly decreased in patients with inv(16)/t(16;16) receiving 3–4 cycles of HDAC as compared with those receiving one HDAC course (43% versus 70%) (Byrd et al., 2004)

Inferior outcome has been reported in patients presenting with high WBC counts (Martin et al., 2000) and older age. (Delaunay et al., 2003)

3.2 Intermediate risk

This comprises the largest cytogenetics group of AML patients. This is because it includes patients excluded from favorable and adverse groups. This translates in wide variation of CR and survival rates. It is believed to be molecularly heterogeneous and advances in molecular analyses of leukemic cell helped identifying subgroups in this large

heterogeneous group. This is particularly important in the largest subset of this group, patient with normal cytogenetics AML.

3.2.1 Normal karyotype

The proportion of adults with de novo AML with normal cytogenetics (AML-NC) has varied between 40% and 49% in various clinical trials which makes the largest cytogenetically defined group of patients.

Fig. 8. Survival curves according to different cytogenetic aberrations for patients treated in MRC AML trials (AML10, 11, 12, 14 and 15) with t-AML and de novo AML (Grimwade & Hill , 2009).

While it is considered as one category in the intermediate risk group, AML-NC represents a heterogeneous group of patients as evident by the wide range of OS rates from 24% to 42%. (Gregory et al., 2009). While certain molecular abnormalities have been identified in AML-NC with prognostic significance that identify distinct subgroups of patients, further efforts are needed to subcategorize the rest of the patients in this heterogeneous group.

3.2.2 Trisomy 8

The prognosis of AML patients with trisomy 8 alone or with other aberrations is still a controversial issue. CR rates of patients with trisomy 8 have differed widely, from 29% to 91% (Schiffer et al., 1989; Dastugue et al., 1995). As a result, some groups such as the MRC and SWOG have assigned these patients to a intermediate risk group whereas the GALGB group consider trisomy 8 in the an unfavorable risk group, See table 3. The differences in prognosis of patients with trisomy 8 reported indicate that this population of patients is heterogeneous and identification of additional prognostic factors are needed.

3.2.3 Others

AML with other non-complex aberrations has been categorized in intermediate risk group due to CR and survival rates that fall between the other two major risk groups. MRC data showed a 10 year survival rate of 37% in patients with less than three aberrations not classified in other risk groups as compared to 38% in patients with normal karyotype, see figure 9b.(Grimwade et al.,2010)

3.3 Adverse risk

10-20% of AML patient have adverse risk cytogenetics. These patients tend to be older, often with a prior history of MDS or exposure to chemotherapy . Different trials have reported CR rates of less 60% and a 5-year survival of around 10%. (Grimwade et al., 2010; Byrd et al., 2002; Slovak et al., 2000)

While there is some variability in additional karyotypes defining unfavorable cytogenetics among different cooperative groups (See table 3), there is agreement on abnormalities of chromosomes 5 and 7 (monosomies of 5 and/or 7 (-5/-7) and deletions of 5q and 7q) ,chromosome 3 abnormalities (inv(3)/t(3;3) and 3q abnormalities except t(3;5)), and complex karyotype.

3.3.1 Chromosome 3 abnormalities

AML with inv(3)/t(3;3) represents approximately 1% to 2% of AML. CR rate has been reported to be < 50% with long term OS < 10%. (Grimwade et al., 2010; Byrd et al., 2002; Slovak et al., 2000). Advanced age and high WBC counts at diagnosis seem to confer an even worse outcome (Weisser et al., 2007).

As part of MDS-related cytogenetic abnormalities per 2008 WHO classification (Swerdlow et al., 2008), all 3q abnormalities have been associated with poor prognosis except for t(3;5). t(3;5) is a rare translocation associated with formation of the NPM1-MLF1 fusion gene. Clinically it occurs mainly occur in younger patients with a median age of 30 years and has a favorable outcome with CR rate exceeding 95%.(Grimwade et al., 2010)

3.3.2 Chromosome 5, 7 abnormalities

Aberrations of chromosomes 5 and 7 (-7/-5, 5q-, 7q-) are seen in 5% and 10% of cytogenetically abnormal AML respectively. There are usually associated with complex karyotype and rarely occur as a sole aberration. There are associated with MDS as well as t-AML related to alkylating agents and radiation. Prognosis is poor especially when part of complex karyotype, see Figure 8. On exception to that if these abnormalities are associated with favorable cytogenetic changes (t(15;17), t(8;21 and inv(16)/t(16;16)). (Heim & Mitelman, 2009)

3.3.3 Complex karyotype

The definition of complex karyotype differs between major cooperative groups while MRC defines it as the presence of a clone with at least five unrelated cytogenetic abnormalities , SWOG/ECOG, CALGB and AMLCG all go with three or more abnormalities. Although the outcome of patients with three or four abnormalities [other than t(8;21), inv(16)/t(16;16) or t(9;11)(p22;q23)] was better when compared to that of patients with five or more abnormalities, both were grouped together due to the dismal prognosis in both (See figure 9).

3.3.4 11q23

Aberrations of chromosome band 11q23 occur in approximately 5% to 10% of adults with AML. In the current WHO classification, AML with these aberrations are regarded as a distinct entity. These aberrations occur in de novo as well as in therapy-related AML especially after treatment with topoisomerase II inhibitors. Aberrations of 11q23 commonly affect the MLL gene (also called HTRX, HRX, TRX1, and ALL-1). A special feature of the MLL translocations in AML is the large diversity of fusion partners. More than 50 different partner genes on various chromosomes have been described. The most common of those are *AF9* in the t(9;11) and *AF6* in the t(6;11). (Krauter et al., 2009).

Fig. 9. Survival curves according to the complexity of cytogenetics. a: Patients treated in CALGB 8461, trial I (Byrd et al., 2002) b: Patients treated in MRC AML trials (AML10, 12, and 15) (Grimwade et al., 2010).

While initially regarded of poor prognosis as a whole group, outcome of AML with 11q23 band aberrations differs according to the fusion partner. While t(6;11)(q27;q23) and t(10;11)(p12;q23) are associated with a poor prognosis in a number of studies (Martineau et al., 1998; Grimwade et al., 2010; Blum et al., 2004), t(9;11)(p22;q23) is considered of intermediate prognosis. Different trials have shown CR rates of of 79-84% and 10-year survival of about 39%. (Grimwade et al., 2010; Byrd et al., 2002)

4. Gene mutations

As previously stated, AML is a heterogeneous disease with variable outcome in each subgroup. Recent advances in molecular technology have revolutionized our understanding of AML biology and prognosis. It has been of great help in defining biological and clinically discrete subgroups especially in the heterogeneous group of AML-NC. It also provides new insight on new possible therapeutic targets. The impact of newly recognized gene mutations on the understanding of AML biology is evident by adding provisionally new subtypes of AML in the new WHO classification of myeloid neoplasms (i.e. AML with mutated NPM1

and AML with mutated CEBPA) (Swerdlow et al., 2008). The prognostic significance of certain mutation is evident by the new genetic risk grouping proposed by European LeukemiaNet (ELN) which divide AML-NC to subgroups according to associated mutations and put them in different risk groups. (Dohner et al., 2010)

4.1 FLT3

FMS-like tyrosine kinase 3 (*FLT3*) gene encodes a member of the class III receptor tyrosine kinase family that is normally expressed on the surface of hematopoietic progenitor cells and plays an important role in the survival and differentiation of multipotent stem. First described by Nakao et al in 1996, mutations in *FLT3* are among the most common genetic mutations in AML with prevalence of 30 - 40% (Nakao et al, 1996; Gregory et al., 2009).

Mutations affect one of two functional domains of the receptor, the juxtamembrane domain (JMD) and the activation loop of the tyrosine kinase domain (TKD). The most common mutation in the JMD of the *FLT3* gene is internal tandem duplications (*FLT3*-ITD) involving JMD with a prevalence of about 25% of adult AML patients. It is particularly more common in AML-NC and AML with t(15;17) where it is reported to in 28-38% and 20-35% respectively. Point mutations affecting TKD and JMD have been reported in about 5-10% and 2% of all AML patients respectively. (Marcucci et al., 2011; Thiede et al., 2002; Schnittger et al., 2002, Mrozek et al., 2007) Clinically, *FLT3*-ITD-positive patients present with increased WBC counts and are more often diagnosed

with de novo than secondary AML. While CR rates are comparable to unmutated AML-CN, prognosis is poor due to high relapse risk. The adverse outcome seen is related to the size of ITD. The longer the duplication the worse the prognosis. (Gregory et al., 2009)

In contrast to *FLT3*-ITD mutations, the prognostic significance of *FLT3*-TKD mutation is still controversial with conflicting conclusions from various studies (Mead et al., 2007; Whitman et al., 2008). In another report from Bacher et al., a neutral impact was seen when looking at all patients with TKD mutation. However in the presence of NPM1 or CEBPA mutation a favorable impact was observed and a negative impact was seen if a TKD mutation occurred in conjunction with MLL-PTD, t (15;17) or *FLT3*-ITD. (Schlenk et al. 2008, Bacher et al., 2008)

In addition to being a prognostic marker, *FLT3*-ITD is a potential therapeutic target. Several small-molecule inhibitors of *FLT3* tyrosine kinase activity in combination with chemotherapy as a frontline therapy for patients with *FLT3* mutation are currently evaluated in phase III clinical trials (Marcucci et al., 2011)

4.2 NPM1

Nucleophosmin (NPM1) is nucleocytoplasmic shuttling protein mainly localized in the nucleolus that has multiple functions involved in cell proliferation, apoptosis, DNA repair and ribosome biogenesis. The NPM1 gene belongs to a new category that functions both as an oncogene and tumor-suppressor gene, depending on gene dosage, expression levels, interacting partners, and compartmentalization. First reported by Falini et al in 2005, NPM1 mutations are very common as they are present in 50% to 60% of patients with AML-NC. (Falini et al, 2005; Gregory et al., 2009; Foran 2010)

Clinically, NPM1 mutations are associated with specific features, including predominance of female sex, higher bone marrow blast percentages, LDH levels, WBC and platelet counts, and high CD33 but low or absent CD34 antigen expression. NPM1 mutations tend to be stable over the disease course, supporting their role as primary lesions in leukemogenesis

and accordingly is recognized as a provisional entity in the 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia. (Swerdlow et al., 2008).

Of notice, FLT3-ITD mutation is detected in approximately 40% of patients with NPM1 mutations. Mutated NPM1 without concurrent FLT3-ITD has been associated consistently with achievement of CR and favorable outcome comparable to CBF AML. (Smith et al., 2011). On the basis of this observation, AML with mutated NPM1 without FLT3-ITD has then recently been allocated to the genetic favorable-risk category of AML together with CBF AML in the new classification suggested by ELN. On the other hand, NPM1 mutations did not impact the poor outcome of patients with FLT3-ITD mutation. (Marcucci et al., 2011; Foran 2010)

4.3 CEBPA

The transcription factor CCAAT enhancer-binding protein alpha (CEBPA) is a key molecule in the mediation of lineage specification and differentiation of multipotent myeloid progenitors into mature neutrophils. Mutations in CEBPA were first identified in AML in a report from Pabst et al in 2001 . Reports following indicate 5% to 10% of de novo AML have this mutation with higher prevalence in AML-NC (15-20%). (Pabst et al., 2001; Fröhling et al., 2004; Foran 2010)

AML-NC patients carrying a CEBPA mutation are characterized by distinct clinical features such as higher peripheral blood blast counts, lower platelet counts, less lymphadenopathy, or extramedullary leukemia. As compared to NPM1 mutations, CEBPA mutations are less frequently associated with FLT3-ITD or TKD mutations. (Schlenk et al., 2008)

In the absence of a FLT3-ITD, CEBPA mutation has a favorable prognosis in patients with AML-NC with approximately 60% long-term survival. Prognosis is better if the mutation is biallelic, where it is categorized in the favorable risk group. (Dufour et al., 2010; Foran 2010; Smith et al., 2011)

4.4 KIT

KIT is the receptor for stem cell factor (KIT ligand) and is expressed on less than 5% of marrow cells. KIT mutation is frequently noted in CBF leukemia with prevalence of 30-40% and 20-30% in inv(16)/t(16;16) and t(8;21) leukemia respectively.

Clinically, Patients affected appear to have higher WBC counts and higher frequency of extramedullary disease such as paraspinal masses. (Foran 2010; Smith et al., 2011). Recent trials have reported significantly higher incidence of relapse and significantly lower survival in CBF leukemia harboring KIT mutation (Schnittger et al., 2006; Baschka et al., 2006). Clinical trials are currently underway evaluating KIT inhibitors in CBF leukemias. (Marcucci et al., 2011)

5. Future perspectives

Advances in molecular studies have changed our understanding of AML as a single disease. As discussed in previous section , certain gene mutations has fragmented previously known risk groups into smaller and more homogenous groups. Identification of new mutations and understanding their prognostic and predictive value is a major goal in AML research. In addition, gene and microRNA expression profiling is a very active area of research in AML with interesting recent observations. We hope that such advances will provide us with more

information that will help in systematic characterization of cancer genomes. We will review briefly few areas of active research showing promising results that need further efforts before it has its practical implications as prognostic and predictive tools.

5.1 Gene mutations

Further gene mutations have been identified in recent trials which are still waiting further clinical data to support their prognostic implications.

5.1.1 IDH1/IDH2 mutations

IDH1/IDH2 gene mutations, which were first reported in gliomas with good prognostic impact, have been recognized recently in AML with aggregate frequency of these two mutations of about 15% to 20% of all patients with AML and 25% to 30% of patients with AML-NC. There are conflicting data concerning the prognostic significance of IDH mutations in AML, with some studies suggesting that they are associated with a poorer outcome especially in NPM1 mutated AML, while others have found no evidence of that (Marcucci et al., 2010; Thol et al., 2010). Further studies with larger number of patients harboring this mutation are needed to further characterize the prognostic significance of this rare mutation.

5.1.2 CBL mutation

The Casitas B-cell lymphoma (CBL) gene on chromosome 11q23.3 contains several functional domains. One of these domains, the C-terminal domain, gives rise to the CBL protein which has ubiquitin ligase activity that targets a variety of tyrosine kinases for degradation by ubiquitination. Heterozygous CBL mutations have been recognized in 0.6% to 33% of AML patient (Sargin et al., 2007; Bacher et al., 2010; Ghassemifar et al., 2011). Interestingly, CBF AML patients represented a significant proportion of patients who have this mutation. (Abbas et al., 2008; Reindel et al., 2009). In one retrospective review including more than two hundred AML patients along with similar number of MDS and MDS/MPD diseases, the presence of CBL mutation was an independent adverse prognostic factor for OS. (Makishima et al., 2009)

5.2 Gene expression profiling

In addition to structural genetic aberrations, changes in expression of specific genes seem to impact prognosis of molecular subsets of patients with AML. Increased or decreased expression of specific genes (typically those involved in hematopoiesis, myeloid differentiation, or immune response) has been associated with response to therapy as well as survival.

5.2.1 BAALC

The brain and acute leukemia cytoplasmic (BAALC) gene is localized on chromosome band 8q22.3. It has been postulated to function in the cytoskeleton network due to its cellular location. It is most commonly seen in AML with trisomy 8 and AML-NC. Several studies have demonstrated that high BAALC expression is a poor prognostic indicator in AML-NC for such factors as OS, DFS, and resistant disease. BAALC expression appears to be particularly useful as a prognostic marker in AML-NC patients lacking FLT3-ITD and CEBPA mutations. (Mrozek et al., 2007; Gregory et al., 2009)

5.2.2 MN1

The meningioma 1 (MN1) gene encodes a protein that participates in a gene transcription regulator complex involving retinoid receptors. Recent studies have shown MN1 overexpression is associated with poor prognosis in AML in terms of response to induction chemotherapy, relapse rate and therefore OS. Interestingly, one study has shown low MN1 expression was correlated with better response therapy in AML. Together, both observations suggest that MN1 expression is not only a prognostic but also a predictive marker for response to treatment. (Foran 2010; Marcucci et al., 2011)

5.2.3 ERG

The ETS-related gene (ERG) is a member of the ETS family of transcription factors. High ERG expression is associated with the upregulation of many genes which are involved in cell proliferation, differentiation, and apoptosis. ERG overexpression mostly impacted outcome of low molecular risk AML-NC (mutated NPM1 without FLT3-ITD) and AML with low BAALC expression. (Gregory et al., 2009; Marcucci et al., 2011)

5.3 MicroRNA expression

MicroRNAs are noncoding RNAs of 19 to 25 nucleotides in length that regulate gene expression. They perform critical functions in cell development, differentiation, proliferation, and apoptosis. They have been shown to play a role in malignant transformation in solid malignancies. Recent studies in AML have shown that specific patterns of microRNA expression are closely associated with certain cytogenetics and molecular changes like FLT3-ITD. Results are reproduced and such patterns are considered like signatures. For example in two separate studies, upregulation of microRNAs expression from genes localized at chromosome band 14q32 has been found in APL with t(15;17) while the downregulation of certain microRNAs (*miR-133a*) was observed in patients with t(8;21). In AML-NC, specific microRNAs expression signature (*miR-155*) was associated with the presence of high risk features (lack of NPM1 mutation or the presence of FLT3-ITD), while upregulation of microRNAs (*miR-181*) was identified in CEBPA mutated AML. (Foran 2010; Marcucci et al., 2011)

6. Conclusion

AML is markedly heterogeneous disease with variable response to therapy and survival. While advances in AML therapy have been moving slowly over last few decades, there have been dramatic breakthroughs in the identification of reproducible prognostic variables in AML. In particular, advances in molecular biology as well as genomics technology have revolutionized our approach to AML and have added substantially to our understanding of biology and prognosis of this disease through identification of novel prognostic markers. This is particularly important in AML-NC which comprises a large heterogeneous group of patients. While such advances help separating AML patients into smaller homogenous groups, we hope to look for a day where individualized therapy for patients AML can be tailored to achieve the best outcome. Such breakthroughs facilitate risk-stratified approach to therapy in AML where more groups are separated into favorable or poor risk groups rather staying the large grey intermediate group. They also provide us with insight into potential therapeutic targets that can be assessed in clinical trials on which we largely depend to achieve breakthroughs.

7. References

- Abbas S, Rotmans G, Lowenberg B, & Valk PJ. *Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias*. *Haematologica*. 2008;93:1595-1597
- Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, & Fenaux P; European APL Group. *Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience*. *Blood*. 2010;115(9):1690-6
- Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlander N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK, eds. *SEER Cancer Statistics Review, 1975-2007*, National Cancer Institute. Bethesda, MD. From http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER website, 2010.
- American Cancer Society: Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society, 2010.
- Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, & Petersdorf SH. *Age and acute myeloid leukemia*. *Blood*. 2006;107(9):3481-5.
- Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, & Estey EH. *The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations*. *Br J Haematol*. 2006;135(2):165-73
- Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, & Ohno R. *Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy*. *Japan Adult Leukemia Study Group*. *J Clin Oncol*. 1998;16(1):78.
- Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, & Haferlach T. *Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies*. *Ann Hematol*. 2010;89(7):643-52.
- Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF & Lancet JE. *Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome*. *Cancer*. 2011;117:1463-1469.
- Blum W, Mrózek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, & Bloomfield CD. *Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature*. *Cancer*. 2004;101(6):1420-7.
- Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, & Kantarjian H. *Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia*. *Cancer*. 2009;115(14):3217-21.
- Burnett AK, Grimwade D, Solomon E, Wheatley K, & Goldstone AH. *Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial*. *Blood*. 1999;93(12):4131-43.

- Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, & Bloomfield CD. *Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.* J Clin Oncol. 1999;17:3767-75.
- Byrd, J.C., Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, & Bloomfield CD. *Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.* J Clin Oncol. 2004;22:1087-1094.
- Chang H, Brandwein J, Yi QL, Chun K, Patterson B, & Brien B. *Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome.* Leuk Res. 2004;28:1007-1011
- Dalley CD, Lister TA, Cavenagh JD, & Rohatiner AZ. *Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.* Br J Cancer 2001;84(1):147.
- De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, & Fenaux P, European APL Group. *Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.* Br J Haematol. 2000;111(3):801
- Delaunay, J., Vey, N., Leblanc, T., Fenaux, P., Rigal-Huguet, F., Witz, F., Lamy, T., Auvrignon, A., Blaise, D., Pigneux, A., Mugneret, F., Bastard, C., Dastugue, N., Van den, A.J., Fiere, D., Reiffers, J., Castaigne, S., Leverger, G., Harousseau, J.L., & Dombret, H. French Acute Myeloid Leukemia Intergroup. *Prognosis of inv(16) t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.* Blood. 2003;102:462-469.
- Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, & Bloomfield CD. *European LeukemiaNet Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.* Blood. 2010;115(3):453-74.
- Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, & Spiekermann K. *Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.* J Clin Oncol. 2010;28(4):570-7.
- Estey E. (2007). *Acute myeloid leukemia and myelodysplastic syndromes in older patients.* J Clin Oncol. 2007;25(14):1908-15.
- Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettrossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, & Martelli MF; GIMEMA Acute Leukemia Working Party. *Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.* N Engl J Med. 2005;352(3):254-66.
- Foran JM. *New prognostic markers in acute myeloid leukemia: perspective from the clinic.* Hematology Am Soc Hematol Educ Program. 2010;2010:47-55.

- Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, & Döhner K. *CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations*. N Engl J Med. 2005;352(3):254-66.
- Ghassemifar R, Thien CB, Finlayson J, Joske D, Cull GM, Augustson B, & Langdon WY. *Incidence of c-Cbl mutations in human acute myeloid leukaemias in an Australian patient cohort*. Pathology. 2011;43(3):261-5.
- Goldstone A, Burnett A, Avivi I, Hills R, & Wheatley K. *Secondary acute myeloid leukemia has a worse outcome than de novo AML, even taking into account cytogenetics and age: AML 10, 11, 12 MRC Trials*. Blood. 2002;100:88a
- Gonzalez JD & Lowenberg B. *Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome*. Blood. 2010;115:5137-5146.
- Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, & Tse W. *Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics*. J Hematol Oncol. 2009;2:23
- Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, & Goldstone A. *The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial*. Blood. 1998;92(7):2322-33.
- Grimwade D & Hills RK. *Independent prognostic factors for AML outcome*. Hematology Am Soc Hematol Educ Program. 2009:385-95.
- Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, & Burnett AK; National Cancer research Institute Adult Leukaemia Working Group. *Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials*. Blood. 2010;116(3):354-65
- Heim V & Mitelman F. (2009). *Cancer Cytogenetics: Chromosomal and Molecular Genetic Abberations of Tumor Cells*. 3rd edition. Wiley-Blackwell. 9780470181799. New Jersey.
- Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). *SEER Cancer Statistics Review, 1975-2008*, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/ , based on November 2010 SEER data submission, posted to the SEER web site, 2011
- Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. *intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia*. Blood. 2010;116(22):4422-9.
- Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, & Schlenk RF; German-Austrian AMLSG. *The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML*. Blood. 2011;117(7):2137-45.
- Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, &

- Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators. *Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes*. Lancet. 2010;376(9757):2000-8.
- Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, & Willman CL. *Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study*. Blood. 1997;89(9):3323-9.
- Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, & Mandelli F, Italian GIMEMA Cooperative Group. *Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group*. Blood. 2010;116:3171-3179.
- Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, & Maciejewski JP. *Mutations of E3 ubiquitin ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies*. J Clin Oncol 2009;27: 6109-16.
- Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, & Bloomfield CD. *Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study*. J Clin Oncol. 2005;23 (24):5705-17.
- Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, & Bloomfield CD. *IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study*. J Clin Oncol. 2010;28(14):2348-55.
- Marcucci G, Haferlach T, & Döhner H. *Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications*. J Clin Oncol. 2011;29(5):475-86.
- Martin G, Barragan E, Bolufer P, Chillon C, Garcia-Sanz R, Gomez T, Brunet S, Gonzalez M, & Sanz MA. *Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement*. Haematologica. 2000;85(7):699-703.
- Martineau M, Berger R, Lillington DM, Moorman AV, & Secker-Walker LM. *The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. EU Concerted Action 11q23 Workshop participants*. Leukemia 1998;12(5):788-91.
- Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, & Gale RE. *FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia*. Blood. 2007;110(4):1262-70.
- Menzin J, Lang K, Earle CC, Kerney D, & Mallick R. *The outcomes and costs of acute myeloid leukemia among the elderly*. Arch Intern Med. 2002;162(14):1597-603.
- Mrózek K, Heinonen K, & Bloomfield CD. *Clinical importance of cytogenetics in acute myeloid leukaemia*. Best Pract Res Clin Haematol. 2001;14: 19-47.

- Mrózek K, Marcucci G, Paschka P, Whitman SP, & Bloomfield CD. *Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?* Blood. 2007;109(2):431-48.
- Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, & Misawa S. *Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.* Leukemia. 1996;10(12):1911-8.
- Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fièrè D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, & Dombret H. *A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.* Blood. 2002;99(10):3517-23.
- Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, & Tenen DG. *Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.* Nat Genet. 2001;27(3):263-70.
- Palmieri S, Sebastio L, Mele G, Annunziata M, Annunziata S, Copia C, Viola A, De Simone M, Pocali B, Schiavone EM, & Ferrara F. *High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).* Leuk Res. 2002;26:539-43.
- Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, & Larson RA, Bloomfield CD; Cancer and Leukemia Group B. *Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.* J Clin Oncol. 2006;24:3904 -3911.
- Pulte D, Gondos A, & Brenner H. *Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century.* Haematologica. 2008;93(4):594-600.
- Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthous T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, & Spiekermann. *CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.* Clin Cancer Res. 2004;15:2238-2247
- Sanz MA, Montesinos P, Rayon C, Holowiecka A, De la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, Gonzalez J, Diaz Mediavilla J, Rojas R, Manso F, Ossenkoppele G, Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M, Thiessen C, Tickenbrock L, Schwäble J, Brandts C, August B, Koschmieder S, Bandi SR, Duyster J, Berdel WE, Müller-Tidow C, Dikic I, & Serve H. *Flt3-dependent transformation by inactivating c-Cbl mutations in AML.* Blood. 2007;110(3):1004-12
- Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, & Testa JR. *Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.* Blood. 1989;73:263-70.
- Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahle R, Pasold R, Döhner K, Ganser A, Döhner H, & Heil G. *Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.* J Clin Oncol. 2004;22(18): 3741-50.
- Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, & Döhner H; German-

- Austrian Acute Myeloid Leukemia Study Group. *Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia*. N Engl J Med. 2008;358:1909–1918.
- Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, & Hiddemann W. *Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease*. Blood. 2002;100(1):59–66.
- Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, & Schoch C. *KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival*. Blood. 2006;107:1791–1799.
- Schoch C, Haase D, Haferlach T, Gudat H, Buchner T, Freund M, Link H, Lengfelder E, Wandt H, Sauerland M, Löffler H, & Fonatsch C. *Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor*. Leukemia. 1996;10:1288–1295.
- Schoch C, Kern W, Schnittger S, Hiddemann W, & Haferlach T. (2004) *Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML*. Leukemia. 2004;18(1):120–5.
- Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, & Haferlach T. *The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups*. Haematologica. 2004;89(9):1082–90.
- Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, & Bloomfield CD. *Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study*. J Clin Oncol. 1997;15(5):1786.
- Smith ML, Hills RK, & Grimwade D. *Independent prognostic variables in acute myeloid leukaemia*. Blood Rev. 2011;25(1):39–51.
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, & Vardiman JW. (2008). *WHO classification of tumours of haematopoietic and lymphoid tissues*. 4th ed.: IARC; 9789283224310, Lyon.
- Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, & Illmer T. *Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis*. Blood. 2002;99(12):4326–35.
- Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, & Ganser A. *Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia*. Blood. 2010;116(4):614–6.
- Weisser M, Haferlach C, Haferlach T, & Schnittger S. *Advanced age and high initial WBC influence the outcome of inv(3)(q21q26)/t(3;3)(q21;q26) positive AML*. Leuk Lymphoma. 2007;48:2145–2151.
- Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, & Bloomfield CD. *FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications*. Blood. 2008;111(3):1552–9.

Myeloid Leukemia - Clinical Diagnosis and Treatment

Edited by Dr Steffen Koschmieder

ISBN 978-953-307-886-1

Hard cover, 296 pages

Publisher InTech

Published online 05, January, 2012

Published in print edition January, 2012

This book comprises a series of chapters from experts in the field of diagnosis and treatment of myeloid leukemias from all over the world, including America, Europe, Africa and Asia. It contains both reviews on clinical aspects of acute (AML) and chronic myeloid leukemias (CML) and original publications covering specific clinical aspects of these important diseases. Covering the specifics of myeloid leukemia epidemiology, diagnosis, risk stratification and management by authors from different parts of the world, this book will be of interest to experienced hematologists as well as physicians in training and students from all around the globe.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Muath Dawod and Amr Hanbali (2012). Prognosis and Survival in Acute Myelogenous Leukemia, Myeloid Leukemia - Clinical Diagnosis and Treatment, Dr Steffen Koschmieder (Ed.), ISBN: 978-953-307-886-1, InTech, Available from: <http://www.intechopen.com/books/myeloid-leukemia-clinical-diagnosis-and-treatment/prognosis-and-survival-in-acute-myelogenous-leukemia>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen